Lung Cancer

The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…

Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…

VJOncology are thrilled to present our top picks from the the IASLC 2022 World Conference on Lung Cancer (WCLC) congress!

VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of  mobocertinib for patients with metastatic non-small cell lung…

Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.

VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

VJOncology are pleased to bring you our top picks from the recent virtual WCLC meeting

Advances in treatment options for anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) have improved patient outcomes considerably in…

The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung…

The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the…

Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth…

The early detection of lung cancer is an exciting field with the potential to greatly improve patient survival. The topic…